Nate Hardy Joins Arsenal Biosciences As CFO
16 Sep 2024 //
BUSINESSWIRE
ArsenalBio Snags Mega $325M Series C Round With Backing from Nvidia, Regeneron
04 Sep 2024 //
BIOSPACE
ArsenalBio Announces $325M Financing for Programmable Cell Therapy Development
04 Sep 2024 //
BUSINESSWIRE
ArsenalBio Announces Presentation of Abstracts at ASGCT Annual Meeting
06 May 2024 //
BUSINESSWIRE
ArsenalBio Announces Presentations Highlighting Data on AB-1015
16 May 2023 //
BUSINESSWIRE
ArsenalBio Announces Presentation of Six Abstracts at AACR
14 Apr 2023 //
BUSINESSWIRE
Thermo Fisher, Arsenal Partner to Manufacture Autologous T-Cell Therapies
29 Mar 2023 //
CONTRACT PHARMA
ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015
05 Jan 2023 //
BUSINESSWIRE
ArsenalBio lands $70M deal with cancer giant Genentech to develop cell therapy
28 Sep 2022 //
ENDPTS
Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech
27 Sep 2022 //
BUSINESSWIRE
BMS-backed Arsenal Bio raises $220M touting refined cell therapy
06 Sep 2022 //
FIERCEBIOTECH
Arsenal Biosciences to Present at the 2022 Jefferies Healthcare Conference
02 Jun 2022 //
BUSINESSWIRE
Bristol Myers inks $3B in Century, ArsenalBio cell therapy deals
11 Jan 2022 //
FIERCEBIOTECH
Arsenal Completes Sale of BioIVT to Linden
05 Oct 2021 //
PRNEWSWIRE
Genentech alum Jane Grogan goes startup hopping from ArsenalBio to Graphite Bio
29 Apr 2021 //
ENDPTS
ArsenalBio Announces Appointment of John Schroer as Chief Financial Officer
08 Mar 2021 //
BUSINESSWIRE
ArsenalBio inks collab with BMY`S to advance next-generation T cell therapies
08 Jan 2021 //
PHARMABIZ
ArsenalBio Announces Multi-Program Discovery Collab with Bristol Myers Squibb
07 Jan 2021 //
PRESS RELEASE
Arsenal Completes BresMed Acquisition; First Step to the Creation
26 Feb 2020 //
PR NEWSWIRE